Compounds > oxazoles
Page last updated: 2024-08-21

oxazoles and bms 207940

oxazoles has been researched along with bms 207940 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Buchhorn, R; Hulpke-Wette, M1
Barrish, JC; Bird, E; Chen, P; Chong, S; Gu, Z; Hermsmeier, M; Humphreys, WG; Koplowitz, B; Leith, L; Liu, EC; Marino, A; Mathur, A; Moreland, S; Morrison, RA; Murugesan, N; Spergel, S; Trippodo, N; Waldron, T; Webb, ML; Young, M; Zhang, R1
Donahue, S; Hughes, D; Tay, LK; Zhou, YS1
Huang, MH; Hughes, DE; Macor, JE; Shi, Y1
Dannals, RF; Hilton, J; Mathews, WB; Murugesan, N; Ravert, HT; Scheffel, U; Szabo, Z; Xia, J1

Reviews

1 review(s) available for oxazoles and bms 207940

ArticleYear
BMS-193884 and BMS-207940 Bristol-Myers Squibb.
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:7

    Topics: Animals; Clinical Trials as Topic; Drug Industry; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension, Pulmonary; Oxazoles; Sulfonamides

2002

Other Studies

4 other study(ies) available for oxazoles and bms 207940

ArticleYear
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
    Journal of medicinal chemistry, 2003, Jan-02, Volume: 46, Issue:1

    Topics: Administration, Oral; Animals; Blood Pressure; Caco-2 Cells; Carotid Arteries; CHO Cells; Cricetinae; Endothelin Receptor Antagonists; Humans; In Vitro Techniques; Isoxazoles; Macaca fascicularis; Male; Muscle Contraction; Oxazoles; Rabbits; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Structure-Activity Relationship; Sulfonamides

2003
Simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist.
    Journal of clinical pharmacology, 2004, Volume: 44, Issue:7

    Topics: Administration, Oral; Area Under Curve; Crystallography, X-Ray; Endothelin Receptor Antagonists; Half-Life; Humans; Injections, Intravenous; Metabolic Clearance Rate; Oxazoles; Stereoisomerism; Sulfonamides

2004
Characterization of the in vitro atropisomeric interconversion rates of an endothelin A antagonist by enantioselective liquid chromatography.
    Journal of chromatography. A, 2005, Jun-17, Volume: 1078, Issue:1-2

    Topics: Biphenyl Compounds; Blood Proteins; Chromatography, High Pressure Liquid; Endothelin A Receptor Antagonists; Half-Life; Humans; Kinetics; Lasers; Molecular Conformation; Oxazoles; Spectrophotometry, Ultraviolet; Stereoisomerism; Sulfonamides

2005
Synthesis and in vivo evaluation of novel PET radioligands for imaging the endothelin-A receptor.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008, Volume: 49, Issue:9

    Topics: Animals; Benzamides; Carbon Radioisotopes; Endothelin A Receptor Antagonists; Fluorine Radioisotopes; Isotope Labeling; Ligands; Male; Metabolic Clearance Rate; Mice; Molecular Probe Techniques; Organ Specificity; Oxazoles; Papio; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, Endothelin A; Sulfonamides; Tissue Distribution

2008